Listed

Sanofi: Form 20-F for the period ended Dec 31, 2018

Filed with the SEC on Mar 8, 2019 and accepted by EDGAR at Mar 8, 2019, 14:30 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2018-01-01 to 2018-12-31EUR 11.44bnifrs-full:CostOfSales
Gross profit12 months2018-01-01 to 2018-12-31EUR 24.24bnifrs-full:GrossProfit
Operating income12 months2018-01-01 to 2018-12-31EUR 4.68bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2018-01-01 to 2018-12-31EUR 481.0mifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2018-01-01 to 2018-12-31EUR 4.31bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2018-01-01 to 2018-12-31EUR 3.43ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2018-01-01 to 2018-12-31EUR 3.45ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2018-01-01 to 2018-12-31EUR 5.55bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2018-12-31EUR 6.92bnifrs-full:CashAndCashEquivalents
Total assetsAt period end2018-12-31EUR 111.41bnifrs-full:Assets
Shareholders' equityAt period end2018-12-31EUR 58.88bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2018-12-311,245,454,385 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-19-068926. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.